Tokai Pharmaceuticals Inc


Stock Update (NASDAQ:TKAI): Tokai Pharmaceuticals Inc and Otic Pharma Enter into Share Purchase Agreement

Tokai Pharmaceuticals Inc (NASDAQ:TKAI) and Otic Pharma Ltd. announced that the two companies, together with the shareholders of Otic Pharma, have entered into …

Stock Update (NASDAQ:TKAI): Tokai Pharmaceuticals Inc Announces Review of Strategic Alternatives

Tokai Pharmaceuticals Inc (NASDAQ:TKAI), a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases, today announced …

Company Update (NASDAQ:TKAI): Tokai Pharmaceuticals Inc Reports First Quarter 2016 Financial Results

Tokai Pharmaceuticals Inc (NASDAQ:TKAI), a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases, today …

Stock Update (NASDAQ:TKAI): Tokai Pharmaceuticals Inc Announces Oral Presentation on Galeterone at the 2016 AUA Annual Meeting

Tokai Pharmaceuticals Inc (NASDAQ:TKAI), a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases, today announced …

Stock Update (NASDAQ:TKAI): Tokai Pharmaceuticals Inc Names Kelly Lindert, M.D. its Executive Vice President and Head of Development

Tokai Pharmaceuticals Inc (NASDAQ:TKAI), a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases, today announced …

Stock Update (NASDAQ:TKAI): Tokai Pharmaceuticals Inc Reports Full Year 2015 Financial Results

Tokai Pharmaceuticals Inc (NASDAQ:TKAI), a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases, today reported …

Stock Update (NASDAQ:TKAI): Tokai Pharmaceuticals Inc Announces Update on ARMOR3-SV and Expanded Galeterone Clinical Development Program

Tokai Pharmaceuticals Inc (NASDAQ:TKAI) provided an update on its clinical development program evaluating galeterone in the treatment of men with metastatic castration-resistant prostate cancer …

Stock Update (NASDAQ:TKAI): Tokai Pharmaceuticals Inc Reports Third Quarter 2015 Financial Results

Tokai Pharmaceuticals Inc (NASDAQ:TKAI), a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases, today reported …

Company Update (NASDAQ:TKAI): Tokai Pharmaceuticals Inc Augments Commercialization Capabilities through Appointment of Lisa Taylor as Senior Vice President, Commercial Development

Tokai Pharmaceuticals Inc (NASDAQ:TKAI), a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally-driven diseases, today announced …

Company Update (NASDAQ:TKAI): Tokai Pharmaceuticals Inc Reports 2Q:15 Results

Tokai Pharmaceuticals Inc (NASDAQ:TKAI), a biopharmaceutical company focused on developing and commercializing proprietary therapies for prostate cancer and other hormonally driven diseases, today reported …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts